View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

AbbVie Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Abbvie Inc: 1 director

A director at Abbvie Inc sold 21,082 shares at 176.300USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

AbbVie Inc.: Update to credit analysis following ImmunoGen and Cerevel...

Our credit view of this issuer reflects its strong competitive position and solid cash flow tempered by execution risk related to the acquisitions of ImmunoGen and Cerevel.

AbbVie Inc. - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's affirms AbbVie's A3 rating; stable outlook

Moody's Investors Service ("Moody's") affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, issuer rating and the Prime-2 senior unsecured commercial paper ratings. The outlook is maintained at stable. These actions follow the announcement that AbbVie will acquire C...

Moody's: AbbVie's ImmunoGen acquisition enhances oncology franchise wi...

Moody's Investors Service commented that AbbVie Inc.'s announcement that it will acquire ImmunoGen, Inc. for approximately $10.1 billon will enhance its oncology franchise by adding the approved drug Elahere to AbbVie's portfolio. The acquisition also brings oncology pipeline opportunities including...

AbbVie Inc.: ImmunoGen acquisition enhances oncology franchise with on...

The acquisition provides a growing oncology drug with blockbuster potential and keeps debt/EBITDA within our expectations

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

AbbVie Inc.: Key facts and statistics - LTM June 2023

A summary company profile, detailing AbbVie Inc.’s business operations and financial highlights.

AbbVie Inc. - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AbbVie Inc.: Update to credit analysis following upgrade to A3

Our credit view of this issuer reflects its large scale, immunology focus and solid cash flow, against Humira biosimilar exposure and event risk associated with debt-financed acquisitions.

Moody's upgrades AbbVie to A3; outlook stable

Moody's Investors Service (Moody's) upgraded the senior unsecured long-term ratings of AbbVie Inc. (AbbVie) to A3 from Baa1. At the same time, Moody's affirmed AbbVie's Prime-2 short-term commercial paper rating. Following these actions, the outlook is stable. "The rating upgrade results from ongo...

AbbVie Inc. - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...

AbbVie Inc.: Humira erosion in US underway, but modest for now

Our credit view of this issuer reflects its large global scale and strong cash flow, offset by declining earnings due to US Humira biosimilar competition

AbbVie Inc. - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Riccardo Bindi

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...

AMGN AMGEN INC.
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
Benjaphol Suthwanish ... (+11)
  • Benjaphol Suthwanish
  • Damon Shen
  • Desmond Chong Chee Wai
  • Jessie Guo Yuting
  • Jieqi Liu
  • Jonathan Koh
  • Ken Lee
  • Roy Chen Chengzhi
  • Selvi Ocktaviani
  • Tanaporn Visaruthaphong
  • Ziv Ang Sze Champ

Regional Morning Notes - Tuesday, February 14, 2023

GREATER CHINA Sector Commodities: Hawkish Fed stance weighing on metal prices; slower-than-expected downstream demand recovery. Update Link REIT (823 HK/BUY/HK$54.75/Target: HK$61.71): Rights issue for lower gearing and stronger position for investment opportunities. Minth Group (425 HK/BUY/HK$21.55/Target: HK$30.00): Recovery on easing of chip shortage, reopening of China, and new businesses. Maintain BUY. Target price: HK$30.00. INDONESIA Results Indosat (ISAT IJ/BUY/Rp6,175/Target: Rp8,000):...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch